Anti-tumor effects of 10-hydroxycamptothecinc-treated DC-Hepa1-6 fusion vaccines / 中华肝脏病杂志
Chinese Journal of Hepatology
;
(12): 344-346, 2004.
Artículo
en Chino
| WPRIM
| ID: wpr-259998
ABSTRACT
<p><b>OBJECTIVE</b>To investigate the induction of antitumor immune responses and therapeutic effects of 10-hydroxycamptothecinc-treated (HCPT) DC-Hepa fusion vaccines by DC fused with hepal-6 cell from hepatoma.</p><p><b>METHODS</b>The fused cells were isolated by magnetic cell sorting and adherent culture. Cell apoptosis was detected by Rhodamine123/PI double-labeled assay, CTL activity by 4 h (51)Cr releasing assay. Protective and therapeutic effects of the fusion vaccine to the tumor-bearing mice was also observed.</p><p><b>RESULTS</b>The apoptosis rate was 29.7%+/-4.1% when DC-Hepa fusion vaccine was treated with 50 microg/ml HCPT for 24 h. After treatment with the HCPT-DC-Hepa fusion vaccine, the tumor grew obviously slowly, survival period of the mice was prolonged, induced more potent CTL cytotoxicity, and resisted against the rechallenge of Hepal-6 cells.</p><p><b>CONCLUSION</b>Vaccination with HCPT-DC-Hepa fusion vaccine could elicit potent antitumor responses, which will provide a new approach to the DC-mediated therapeutic antitumor immunity.</p>
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Patología
/
Farmacología
/
Trasplante
/
Células Dendríticas
/
Camptotecina
/
Células Tumorales Cultivadas
/
Linfocitos T Citotóxicos
/
Fusión Celular
/
Apoptosis
/
Vacunas contra el Cáncer
Límite:
Animales
Idioma:
Chino
Revista:
Chinese Journal of Hepatology
Año:
2004
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS